Harrow (NASDAQ:HROW) Shares Down 5.8% – Here’s What Happened

Harrow, Inc. (NASDAQ:HROW) shares traded down 5.8% during mid-day trading on Monday . The company traded as low as $26.46 and last traded at $26.45. 61,732 shares changed hands during mid-day trading, a decline of 81% from the average session volume of 319,487 shares. The stock had previously closed at $28.08.

Analyst Ratings Changes

A number of analysts have commented on HROW shares. B. Riley decreased their price target on shares of Harrow from $73.00 to $69.00 and set a “buy” rating for the company in a research note on Wednesday, December 4th. HC Wainwright assumed coverage on shares of Harrow in a research report on Thursday, February 6th. They set a “buy” rating and a $57.00 target price for the company.

Harrow Price Performance

The company has a current ratio of 1.55, a quick ratio of 1.44 and a debt-to-equity ratio of 3.23. The business has a 50-day moving average of $32.52 and a 200 day moving average of $40.02. The firm has a market capitalization of $912.81 million, a PE ratio of -27.27 and a beta of 0.69.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. GF Fund Management CO. LTD. purchased a new stake in Harrow in the 4th quarter valued at about $25,000. Quest Partners LLC bought a new position in shares of Harrow in the third quarter valued at approximately $29,000. Tower Research Capital LLC TRC increased its position in shares of Harrow by 769.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,652 shares of the company’s stock valued at $55,000 after acquiring an additional 1,462 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Harrow by 21.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,283 shares of the company’s stock worth $57,000 after acquiring an additional 227 shares during the period. Finally, Aquatic Capital Management LLC purchased a new position in Harrow in the fourth quarter worth $78,000. 72.76% of the stock is owned by institutional investors.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.